This observation also provides a plausible explanation for the dual role of Wnt5a described in cancer [51] where it was shown to command a tumor-suppressing effect in colorectal cancer [52], neuroblastoma [53], ductal breast cancer [54], and leukemia [55] and an oncogenic role in melanoma, breast cancer, gastric cancer, pancreatic cancer, non-small-cell lung cancer, and prostate cancer [56, 57]. The gene discussed is WNT5A; the disease is prostate carcinoma.